207 related articles for article (PubMed ID: 28756899)
21. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.
Haverkos BM; Abbott D; Hamadani M; Armand P; Flowers ME; Merryman R; Kamdar M; Kanate AS; Saad A; Mehta A; Ganguly S; Fenske TS; Hari P; Lowsky R; Andritsos L; Jagasia M; Bashey A; Brown S; Bachanova V; Stephens D; Mineishi S; Nakamura R; Chen YB; Blazar BR; Gutman J; Devine SM
Blood; 2017 Jul; 130(2):221-228. PubMed ID: 28468799
[TBL] [Abstract][Full Text] [Related]
22. Utility of routine surveillance imaging for diffuse large B-cell lymphoma post autologous transplant: A single center experience.
Mohyuddin GR; Clark AE; Roller J; Shune L; Lin T; Dunavin N; Dias A; Ganguly S; Abhyankar S; McGuirk J; Singh A
Hematol Oncol Stem Cell Ther; 2018 Sep; 11(3):135-141. PubMed ID: 29278676
[TBL] [Abstract][Full Text] [Related]
23. Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma.
Chen R; Palmer JM; Popplewell L; Shen J; Smith E; Delioukina M; Kogut N; Rosenthal J; Forman S; Nademanee A
Ann Hematol; 2011 Jul; 90(7):803-8. PubMed ID: 21210120
[TBL] [Abstract][Full Text] [Related]
24. High-dose Therapy and Autologous Hematopoietic Cell Transplantation as Consolidation Treatment for Primary Effusion Lymphoma.
Mirza AS; Dholaria BR; Hussaini M; Mushtaq S; Horna P; Ravindran A; Kumar A; Ayala E; Kharfan-Dabaja MA; Bello C; Chavez JC; Sokol L
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):e513-e520. PubMed ID: 31253594
[TBL] [Abstract][Full Text] [Related]
25. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
Shustov A
Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
[TBL] [Abstract][Full Text] [Related]
26. Autologous Hematopoietic Stem Cell Transplantation for Patients with Lymphoma-Associated Hemophagocytic lymphohistiocytosis.
Song Y; Yin Q; Wang J; Wang Z
Cell Transplant; 2021; 30():9636897211057077. PubMed ID: 34743574
[TBL] [Abstract][Full Text] [Related]
27. Pembrolizumab for the Treatment of Relapsed and Refractory Classical Hodgkin Lymphoma After Autologous Transplant and in Transplant-Naïve Patients.
Halahleh K; Al Sawajneh S; Saleh Y; Shahin O; Abufara A; Ma'koseh M; Abdel-Razeq R; Barakat F; Abdelkhaleq H; Al-Hassan N; Atiyyat R; Al-Faker N; Omari Z; Ghatasheh H; Jaradat I; Muradi I; Iyad S; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):589-595. PubMed ID: 35490153
[TBL] [Abstract][Full Text] [Related]
28. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
[TBL] [Abstract][Full Text] [Related]
29. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
30. Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation.
Ahmed S; Zhao Q; Hanel W; Qazilbash MH; Patel K; Narra R; Kansagra A; Iqbal M; Awan FT; Christian B; Jaglowski SM; Kharfan-Dabaja MA; Hamadani M; Epperla N
Hematol Oncol; 2022 Feb; 40(1):48-56. PubMed ID: 34763367
[TBL] [Abstract][Full Text] [Related]
31. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.
Naik S; Martinez C; Leung K; Sasa G; Nguyen NY; Wu MF; Gottschalk S; Brenner M; Heslop H; Krance R
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1266-72. PubMed ID: 25765555
[TBL] [Abstract][Full Text] [Related]
32. [Novel treatment options in relapsed and refracter Hodgkin lymphomas].
Illés Á; Jóna Á; Simon Z; Udvardy M; Miltényi Z
Orv Hetil; 2015 Nov; 156(45):1824-33. PubMed ID: 26522856
[TBL] [Abstract][Full Text] [Related]
33. Outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin lymphoma patients in a centre from Turkey.
Sucak GT; Çakar MK; Suyanı E; Akı Z; Altındal Ş; Acar K
Hematology; 2013 Sep; 18(5):269-76. PubMed ID: 23394351
[TBL] [Abstract][Full Text] [Related]
34. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Armand P; Engert A; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman JM; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Shipp MA; Kato K; Sumbul A; Farsaci B; Ansell SM
J Clin Oncol; 2018 May; 36(14):1428-1439. PubMed ID: 29584546
[TBL] [Abstract][Full Text] [Related]
35. Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.
Ram R; Gooley TA; Maloney DG; Press OW; Pagel JM; Petersdorf SH; Shustov AR; Flowers ME; O'Donnell P; Sandmaier BM; Storb RF; Gopal AK
Biol Blood Marrow Transplant; 2011 Oct; 17(10):1537-45. PubMed ID: 21536145
[TBL] [Abstract][Full Text] [Related]
36. Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma.
Fakhri B; Yilmaz E; Gao F; Ambinder RF; Jones R; Bartlett NL; Cashen A; Wagner-Johnston N
Leuk Lymphoma; 2021 Oct; 62(10):2408-2415. PubMed ID: 33988071
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of Hodgkin's lymphoma patients with relapse or progression following autologous hematopoietic cell transplantation.
Kaloyannidis P; Voutiadou G; Baltadakis I; Tsirigotis P; Spyridonidis A; Repousis P; Balta A; Tsimberis S; Karakasis D; Sakellari I; Dervenoulas I; Harhalakis N; Anagnostopoulos A
Biol Blood Marrow Transplant; 2012 Mar; 18(3):451-7. PubMed ID: 21803018
[TBL] [Abstract][Full Text] [Related]
38. Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.
Sun L; Li S; El-Jawahri A; Armand P; Dey BR; Fisher DC; Jacobsen ED; Jacobson CA; LaCasce AS; McAfee SL; Spitzer TR; Chen YB; DeFilipp Z
Oncologist; 2018 May; 23(5):624-630. PubMed ID: 29284757
[TBL] [Abstract][Full Text] [Related]
39. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T
Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
[TBL] [Abstract][Full Text] [Related]
40. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.
Sibon D; Morschhauser F; Resche-Rigon M; Ghez D; Dupuis J; Marçais A; Deau-Fischer B; Bouabdallah R; Sebban C; Salles G; Brice P
Haematologica; 2016 Apr; 101(4):474-81. PubMed ID: 26721893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
